Fallopian tube tumors: an overview

2013-03-01   Roland Gregor Stein , Joachim Diessner , Arnd Hönig , Jörg Wischhusen , Johannes Dietl 

1.Wurzburg University Hospital, Department of Obstetrics, Gynecology, Josef-Schneider-Str. 4, 97080 Wurzburg, Germany

Summary

Note

Introduction
This article shall give an overview of different tumors occurring in the fallopian tube. Though being a very rare location of primary or exclusive tumor manifestation, the fallopian tube is now receiving increased attention in gynecological oncology since considerable evidence suggests that it represents the site-of-origin of many (if not most) serous pelvic carcinomas (Folkins et al., 2009; Dietl and Wischhusen, 2011; Dietl et al., 2011; Seidman et al., 2011; Vang et al., 2013).

Disease definition
A tumor is classified as primary fallopian tube tumor when it is either restricted to this anatomical structure, or when the fallopian tube is most affected whereas co-locations such as ovary and uterus show lesser involvement or a different histology (Alvarado-Cabrero et al., 2003; Folkins et al., 2009). As recent data indicate that the fallopian tube is the site-of-origin of serous pelvic carcinomas (Folkins et al., 2009; Dietl and Wischhusen, 2011; Dietl et al., 2011; Seidman et al., 2011; Vang et al., 2013), histological assessment of the respective involvement of ovaries and fallopian tubes may not be sufficient to distinguish between advanced stages of fallopian tube and ovarian carcinomas (Kosary and Trimble, 2002). Inevitably, the considerable overlap between ovarian and fallopian tube carcinomas warrants some coverage of ovarian cancer in this context. Nevertheless, as ovarian carcinomas constitute a well-accepted clinical entity (irrespective of their potential origin from the fallopian tube) they shall largely be dealt with in a separate place.

Atlas Image
Figure 1: WHO Classification of solid tumors of the fallopian tube (Alvarado-Cabrero et al., 2003).

Classification

Note

Solid fallopian tube tumors can be subcategorized based on origin and behavior. The WHO classification distinguishes several groups of solid tumors of the fallopian tube (Alvarado-Cabrero et al., 2003) shown in Figure 1.
Atlas Image
Table 1: TNM and FIGO Classification of carcinomas of the fallopian tube (UICC, 2009). Table 2: Staging of fallopian tube carcinomas (UICC, 2009).

Classification

Staging
Malignant tumors of the fallopian tube are classified according to the "Union International contre le cancer" (UICC) and the "Fédération internationale de Gynécologie et dObstétrique" (FIGO, Table 1 and 2). The TNM classification is based on clinical and pathological findings whereas the FIGO classification requires a surgical staging (UICC, 2009; AJCC, 2010).
According to the TNM classification, the carcinomas of the fallopian tube approximate different stages (Table 2).

Clinics and Pathology

Etiology

The etiology of primary fallopian tube tumors is unknown. Multiparity seems to be protective (Riska et al., 2003), pregnancies and oral contraceptives decrease the risk (Inal et al., 2004). Neither age, nor weight, education level, pelvic inflammatory disease, infertility, previous hysterectomy or endometriosis show significant correlations especially with fallopian tube carcinomas (Henderson et al., 1977; Demopoulos et al., 2001; Inal et al., 2004). Demographic distribution is similar to ovarian cancer, and the highest incidence was found in white, non-Hispanic women and women aged 60-79. However, recent evidence suggests tubal cancer to be much more frequent (Stewart et al., 2007; Piek et al., 2008).

Epidemiology

Epidemiological data on malignant fallopian tube tumors are adequate, even though only 0.3-1.1% of all gynecological malignancies are typically classified as primary fallopian tube carcinomas (Baekelandt et al., 2000), mostly adenocarcinomas (Schneider et al., 2000). In the U.S., the incidence is about 3.6 per million women per year (Rosenblatt et al., 1989). Stage-adjusted survival rates are generally better than for epithelial ovarian carcinoma (Kosary and Trimble, 2002). Underestimation of the real incidence might be due to fallopian tube carcinomas being mistaken for ovarian cancers (Woolas et al., 1994) which show a significantly higher prevalence. Still, Riska and colleagues reported an increasing incidence of fallopian tube carcinomas from 1.2 per million per year for 1953-1957 to 5.4 per million per year from 1993-1997 (Riska et al., 2003).

Clinics

Atlas Image
Figure 2: Histology of an invasive serous-papillary adenocarcinoma of the fallopian tube. a: Tumor formation in the tubal wall. b shows 200 fold magnification with gland formation (*). c: Metastasis in adipous tissue. d: Immunohistochemistry for Ki67 with nuclear positivity. e and f: Immunohistochemistry for p53 also with nuclear positivity.
Figure 3: a: In this H&E staining, the STIC cells show polymorphic nuclei and a multilayer epithelium (arrowheads) compared with normal tubal epithelium (arrows). b: Distinct transition from normal tubal epithelium to p53 positive STIC (p53 immunohistochemistry). c: Invasive fallopian tube carcinoma (arrowheads) next to STIC formation (arrows, H&E).

Pathology

Benign tumors
Benign tumors are often solid and clearly delimited. They arise at the intraluminal or serosal surface of the fallopian tube.
Papillomas show fibrovascular stacks with epithelial lining. They can obstruct the fallopian tube (Gisser, 1986).
Adenofibromas and cystadenofibromas occur between the third and eighth decade. They remain asymptomatic and are diagnosed incidentally during other operations (Zheng et al., 1996). Macroscopically, these tumors grow to 0.5-3cm and can be intraluminal or at the serosa surface as well as at the fimbriae. They show a stromal and a papillary structured fraction (Alvarado-Cabrero et al., 2003). In fallopian tubes resected post partum, few metaplastic papillary tumors were detected (Saffos et al., 1980; Keeney and Thrasher, 1988; Bartnik et al., 1989). These tumors consist of papillae lined by epithelium displaying patterns of a serous borderline tumor. The cells can be positive for intracellular mucin (Alvarado-Cabrero et al., 2003).
Adenomyomas consist of bundle-like growing leiomyoma cells and sometimes endometrial tissue remnants.
Endometrioid polyps occur in the interstitial part of the tube attached to the intratubal epithelium and sometimes cause infertility (Heller et al., 1991; Heatley, 2001).
Cystadenofibromas can show vimentin-cytokeratin-coexpression. Further, diffuse apical epithelial membrane antigen (EMA) immunoreactivity occurs. Gürbüz et al. suggest that tumors are derived from embryonic remnants of the Müllerian duct (Gürbüz and Ozkara, 2003).

Borderline tumors of the fallopian tube occur very rarely and can show serous, mucinous or endometrioid differentiations. Histological features resemble those in borderline tumors of the ovary (Alvarado-Cabrero et al., 1997). Mucinous tumors of the fallopian tube can be associated with pseudomyxoma peritonei (McCarthy and Aga, 1988), other mucinous lesions or Peutz-Jeghers-Syndrome (Seidman, 1994). There are also reports about adenofibroma with borderline malignancy. The prognosis seems to be favorable (Zheng et al., 1996; Alvarado-Cabrero et al., 1997).

Precursor lesions: Intraepithelial carcinoma
Non-invasive carcinomas of the fallopian tube were formerly known as "carcinoma in situ". This term should be abandoned as it implies restricted local tumor formation. Intraepithelial carcinoma cells can, however, form implants on the ovarian surface and the peritoneum. Recent publications highlight the fallopian tube as likely site-of-origin of primary pelvic serous carcinomas detected in the fallopian tube, the ovary or the peritoneum (Folkins et al., 2009; Dietl and Wischhusen, 2011; Dietl et al., 2011; Seidman et al., 2011; Vang et al., 2013). Serous tubal intraepithelial carcinomas (STIC) as well as endometrioid intraepithelial carcinomas (EIC) are thus considered as precursor lesions (Ambros et al., 1995; Carlson et al., 2008). This hypothesis is supported by findings from Colgan et al. who found a high frequency of pre-cancerous lesions in fallopian tubes from patients with BRCA gene mutations (Colgan, 2003). Lee and colleagues could detect mutant p53-signatures predominantly in epithelial cells at the fimbriated ends of fallopian tubes from patients with BRCA1 and 2 mutations. Moreover, the same signatures were also found in corresponding ovarian cancer tissues (Lee et al., 2007). Interestingly, Li-Fraumeni-Syndrome - which is associated with p53 mutations and generally increased risk for serous carcinomas - does not correlate with a higher incidence of PPSC, especially fallopian tube carcinomas. Thus, it seems that other mutations e.g. those affecting BRCA are required to drive PPSC development (Xian et al., 2010). Kim and colleagues could prove by histology that serous epithelial cancers develop in the fallopian tubes of Dicer-PTEN-double-knockout mice. By histology and pathological behavior these tumors showed characteristic traits of serous epithelial ovarian cancer, even though oophorectomy was not protective. Instead, tumor development could be prevented by salpingectomy (Kim et al., 2012). Furthermore, in prophylactic salpingo-oophorectomy specimen, occult carcinomas are more frequent in the fallopian tube than the ovary (Vang, 2011). While carrying the potential of invasiveness, the STIC cells grow sparing the tubal stroma. Figure 3 focusses on the STIC with its distinct cellular alterations such as polymorphic nuclei, multilayer epithelium and atypic mitoses. Figure 3d also shows an invasive fallopian tube carcinoma with an adjoining STIC.
In clinical studies, a frequent coexistence of pelvic serous carcinoma and tubal intraepithelial carcinomas was found in unselected (Przybycin et al., 2010) and BRCA mutated patients (Kindelberger et al., 2007). Shortening of telomeres is another early event in PPSC development and already detectable in the STIC (Kuhn et al., 2010).
As the post-reproductive fallopian tube lacks physiological functions and also causes complications such as hydrosalpinx, Dietl et al. suggested combined hysterosalpingectomy instead of simple hystercectomy or salpingectomy as a recommendable method for sterilization in clinical routine (Dietl and Wischhusen, 2011; Dietl et al., 2011).

Invasive carcinoma
All tumor subtypes in the ovaries are also known in the fallopian tube, with serous carcinomas being most frequent. In a series of 105 fallopian tube carcinomas Alvarado-Cabrero et al. found the following distribution of different histologies: About 50% were serous, 25% endometrioid, 20% transitional cell or undifferentiated carcinomas and 5% were of other subtypes (Alvarado-Cabrero et al., 1999).
Serous adenocarcinomas are generally invasive with 50% G3 tumors (Alvarado-Cabrero et al., 1999). Sometimes immune cell invasion disguises the tumor as salpingitis (Cheung et al., 1994).
Mucinous adenocarcinomas, a very rare entity, are often associated with other mucinous carcinomas of the female genital tract or the appendix (Seidman, 1994).
Endometrioid adenocarcinomas are very often non-invasive or superficially invasive and show a favorable prognosis (Navani et al., 1996). A part of those tumors displays characteristics of the wolffian adnexal tumor (Daya et al., 1992; Navani et al., 1996).
Clear cell adenocarcinomas account for 2-10% of all fallopian tube carcinomas (Voet and Lifshitz, 1982; Hellstrom et al., 1994; Alvarado-Cabrero et al., 1999).
Transitional cell carcinomas are rare in the genital tract. Still, the frequency between 11 and 43% of all fallopian tube carcinomas makes it an important locus-specific entity (Uehira et al., 1993; Alvarado-Cabrerog et al., 1999).
Undifferentiated carcinomas lack any patterns of squamous cells or glandular cells but instead contain multinuclear giant cells (Alvarado-Cabrero et al., 1999).
Lacy et al. reported immunohistochemical positivity for c-erbB-2 (HER-2/neu) overexpression in 26% and p53 positivity in 61% of all cases in a cohort of 43 patients with fallopian tube carcinoma. There was not significant correlation with survival (Lacy et al., 1995). Ovarian cancer in comparison also shows c-erbB-2 (HER-2/neu) positivity in about 29% of all cases (Lanitis et al., 2012). Others, in contrast, described a correlation between p53 immunohistochemical positivity and shorter survival (Zheng et al., 1997; Rosen et al., 2000). FIGO stages, however, did not correlate with survival in this same cohort of 63 patients (Rosen et al., 2000). Zheng et al. investigated the correlating immunohistochemistry and polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) for p53 in 52 cases of fallopian tube carcinoma and 10 normal fallopian tubes and found that p53 alterations already occur at early stages suggesting a role in early tumor progression (Zheng et al., 1997). Chung and colleagues found that survival neither correlated with immunohistochemical p53 positivity nor with cMyc overexpression (which occured in 61%). However, the statistical power of this study was limited by the small cohort of 18 patients (Chung et al., 2000). Hence, it did not challenge larger studies which proposed that p53 might have an important role especially in familial BRCA-associated cases of fallopian tube carcinomas. Figure 2 shows different pathohistological aspects of a serous adenocarcinoma of the fallopian tube.

Mixed epithelial-mesenchymal tumors
The least common site for malignant Müllerian mixed tumor (carcinosarcoma, metaplastic carcinoma) is the fallopian tube accounting for only 4% of all cases. The prognosis of these mostly postmenopausal patients is poor (Hanjani et al., 1980).
In the literature, only one adenosarcoma has been described in the fallopian tube (Gollard et al., 1995).

Soft tissue tumors
Leiomyosarcomas are very rare as only 37 cases have been reported in 100 years (Jacoby et al., 1993).

Mesothelial tumors
Adenomatoid tumors mostly occur in middle-aged or elderly women (Inoue et al., 2001). In most cases, they remain asymptomatic but can also occlude the lumen. Often, they show gland-like structures with a lining of flat to cuboidal cells (Stephenson and Mills, 1986).

Germ cell tumors
Until 2003, 50 cases of mature or immature teratoma were reported (Alvarado-Cabrero et al., 2003). For malignant mixed germ cell tumors of the fallopian tube, only one single case was published (Li et al., 1999).

Trophoblastic tumors
Only about 4% of choriocarcinomas occur in the fallopian tube (Dekel et al., 1986). About 40% of these go along with adnexal tumors (Ober and Maier, 1981).
In the fallopian tube, hydatiform moles can histologically correspond to a complete, partial or invasive mole (Alvarado-Cabrero et al., 2003).
Placental site nodules as non-neoplastic proliferation of intermediate trophoblast can occur (Alvarado-Cabrero et al., 2003). Intermediate trophoblast tumors can be either benign or malignant (Kurman et al., 1976). Only one case of malignant placental site trophoblastic tumor has been reported in the fallopian tube (Su et al., 1999).

Lymphoid and haematopoietic tumors
Malignant lymphoma and leukemia mostly show an involvement of the ipsilateral ovary (Osborne and Robboy, 1983). 25% of patients with ovary lymphomas had a Burkitt-lymphoma or Burkitt-like lymphoma or a diffuse large-cell lymphoma.

Metastatic tumors
For 89% of secondary tumors in the fallopian tube, the primary tumor was assigned to be of ovarian origin (Woodruff and Julian, 1969). Considering the ongoing paradigm shift which proposes that serous ovarian carcinomas likely originate from the fallopian tube, these figures have to be reconsidered. Many of these tumors may have originated from the fimbriated end of the fallopian tube with a secondary manifestation in the ovary.

Atlas Image
Table 3: Postoperative treatment of fallopian tube carcinoma (Pectasides et al., 2006).

Treatment

Surgical therapy: For fallopian tube tumors and especially for carcinomas, surgical removal is the first line treatment. Whereas benign tumors can usually be resected completely, the approach for fallopian tube carcinomas should be the same as for epithelial ovarian cancer with the aim of complete resection or at least maximum tumor debulking. Special focus should be placed on para-aortic and pelvic lymphadenectomy in regard to the higher rate of lymph node metastases (Yoonessi, 1979; McMurray et al., 1986; Maxson et al., 1987; Asmussen et al., 1988; Peters et al., 1988; Gadducci et al., 2001). Klein and colleagues found a significantly reduced median survival of 21 months versus 43 months in patients who had not undergone lymphadenectomy (Klein et al., 1999).
Radiotherapy: Although radiotherapy for fallopian tube carcinomas could be considered, it is inferior to adjuvant platin compounds containing chemotherapy. Neither irradiation nor intraperitoneal instillation of radioisotopes could prevent relapse (Asmussen et al., 1988). A second look operation with pathological complete remission (pCR) is a predictor for longer survival. 50% of patients with surgical complete remission will ultimately relapse. Thus, second-look operations are not generally beneficial and hence no routine treatment (Takeshima and Hasumi, 2000).
Adjuvant chemotherapy: Baekeland et al. found a 70% response rate to adjuvant platinum-containing chemotherapy in platinum-naive patients with median response duration of 12.5 months. They further suggested to refrain from postoperative radiation therapy due to its low efficacy and high rate of complications (Baekelandt et al., 2000). Kosary et al. gave the general recommendation to treat women with fallopian tube carcinomas like women with epithelial ovarian cancer, i.e. by surgical staging and debulking followed by adjuvant chemotherapy (Kosary and Trimble, 2002). In addition to platinum-based chemotherapy, also paclitaxel is becoming more and more important in the treatment of advanced fallopian tube tumors (Takeshima and Hasumi, 2000). Patients with early stages as IA and IB might not need adjuvant chemotherapy. For all higher stages, adjuvant combined chemotherapy is requested. Two randomized controlled trials (International Collaborative Ovarian Neoplasm 1 (ICON1) and Adjuvant Chemotherapy In Ovarian Neoplasm (ACTION)) compared platinum based adjuvant chemotherapy and mere observation after early stage ovarian cancer surgery and reported 5 year overall survival rates of 74% without and 82% with adjuvant platinum based chemotherapy (Trimbos et al., 2003). This could hint at a survival benefit being associated with adjuvant chemotherapy also for early stage fallopian tube carcinomas. Cisplatin based chemotherapy yielded response rates between 53 and 92 % (Deppe et al., 1980; Raju et al., 1981; McMurray et al., 1986; Maxson et al., 1987; Peters et al., 1988; King et al., 1989; Muntz et al., 1989; Barakat et al., 1993; Pectasides et al., 1994). Several studies also included Paclitaxel in the first line therapy (McMurray et al., 1986; Maxson et al., 1987; Muntz et al., 1991; Ben-Hur et al., 1999; Gemignani et al., 2001). For relapse therapy, data from epithelial ovarian cancer in platinum-pretreated patients also highlights the role of Paclitaxel (Tresukosol et al., 1995; Baekelandt et al., 2000; Ichikawa et al., 2000; Gemignani et al., 2001).
After review of the literature and according to the U.S. guidelines, Pectasides and colleagues suggested an adjuvant standard treatment shown in table 3 (Pectasides et al., 2006).

For the treatment of relapse, platinum-sensitive tumors (relapse after more than 6 months) receive a reinduction with platinum with or without Paclitaxel, whereas patients with platinum-refractory (relapse during therapy) or platinum-resistant tumors (relapse

Prognosis

Prognostic factors for early stage I carcinomas are depth of invasion into the tubal wall and tumor rupture during surgery. Even early stages tend to metastasize to the peritoneum (Baekelandt et al., 2000). The surgical stage is an independent prognostic factor (Alvarado-Cabrero et al., 1999; Baekelandt et al., 2000). Carcinomas of the fimbriae region are afflicted by a worse prognosis than carcinomas of the isthmic region (Alvarado-Cabrero et al., 1997). There are different results concerning the histological grading: Vaughan et al. found a significant correlation between grading and survival (Vaughan et al., 1998), Gadducci et al. could also find this in univariate but not in multivariate analysis (Gadducci et al., 2001). Grading further correlates with lymphogenous metastases (Klein et al., 1999). Lymphocytic infiltration of the tumor correlates with favorable outcome (Rosen et al., 1993). The role of DNA-ploidy is thought to be negligible (Klein et al., 2002).
Fallopian tube carcinoma patients show an overall survival of 30-50% which is slightly better than the reported 25-40% for epithelial ovarian cancer (Momtazee and Kempson, 1968; Baekelandt et al., 1993; Barakat et al., 1993; Woolas et al., 1994; Alvarado-Cabrero et al., 1999; Piura and Rabinovich, 2000). The general 5-year survival rate is about 65% (Sedlis, 1978; Deppe et al., 1980; Inal et al., 2004). Kosary and colleagues found in a cohort of 416 women with fallopian tube carcinoma 5 year-survival rates of 95% for stage I (n=102), 75% for stage II (n=29), 69% for stage III (n= 52) and 45% for stage IV (n=151) (Kosary and Trimble, 2002).

Genetics

Note

Fallopian tube carcinomas can manifest as a consequence of the hereditary breast-ovarian cancer syndrome. They are associated with BRCA1 and BRCA2 mutations. In a cohort of 44 cases of fallopian tube carcinoma, 11% of the patients were positive for BRCA1 mutation and 5% were positive for BRCA2 mutations. Of the patients who received their diagnosis before the age of 55 years, 28% (5/18) were BRCA positive. First degree relatives of fallopian tube cancer patients show an increased risk for early breast and ovarian cancer (Aziz et al., 2001). A BRCA1-carrier patient undergoing prophylactic salpingo-oophorectomy showed a fallopian tube cancer (Hartley et al., 2000). A positive family history of fallopian tube carcinoma was predictive for BRCA1 mutation in 26 Canadian breast-ovarian cancer families (Tonin et al., 1995). Friedman et al. reported fallopian tube carcinomas in 2 of 12 families with BRCA1 mutations (Friedman et al., 1995). Tonin et al. found BRCA1 mutations in four Ashkenazi Jewish breast-ovarian cancer families with fallopian tube carcinoma (Tonin et al., 1996). Zweemer and colleagues detected fallopian tube carcinomas in 2 of 23 families with known BRCA1 mutations (Zweemer et al., 2000).
Thus, genetic evaluation should become part of the diagnostics for patients with fallopian tube carcinomas. In risk patients, prophylactic oophorectomy should be accompanied by salpingectomy (Aziz et al., 2001). And whether salpingectomy without oophorectomy is sufficient treatment will be analyzed in the clinical trials yet to come.
Jongsma and colleagues reported frequent loss of heterozygosity (LOH) on chromosome 13 in BRCA1-associated cases of fallopian tube carcinomas indicating that these areas may contain putative tumor suppressor genes (Jongsma et al., 2002).
Different authors (see above) found that immunohistochemical or PCR-based positivity for p53 alterations correlates with shorter survival (Hellstrom et al., 1994; Zheng et al., 1997; Rosen et al., 2000).

Genes Involved and Proteins

Gene name

BRCA1 (breast cancer 1, early onset)

Location

17q21.31

Dna rna description

6 different mRNA variants that undergo alternative splicing. Splicing influences intracellular function and location. According to ENTREZ Gene, BRCA1 starts at NC_000017.10 (41196312..41277500, complement), Spidey (mRNA to genomic sequence alignment tool, http://www.ncbi.nlm.nih.gov/spidey) finds 24 exons. The mRNA consists of ~81.2kb.

Protein description

The encoded protein functions as intracellular tumor suppressor with E3-ubiquitin ligase- and phosphopeptide binding activity. As a transcription factor, it is a DNA damage sensor forming (together with other proteins) the BRCA1-associated genome surveillance complex (BASC). Germline mutations lead to the familiar breast and ovarian cancer syndrome with highly increased risk for cancer development. Working together with RNA polymerase II, the protein has an important role in transcription, DNA repair of double-stranded breaks, and recombination.
There are five different protein isoforms. Isoform 1 is the biggest with 1863 amino acids and 220 kDa. The highest expression of BRCA1 is found in the ovaries, thymus and testes.

Gene name

BRCA2 (breast cancer 2, early onset)

Location

13q13.1

Dna rna description

According to Spidey, BRCA2 has 27 exons. The mRNA spans about 84.2 kb. In exon 11, the BRC repeats are encoded.

Protein description

Also BRCA2 is involved in DNA stability, especially the double strand repair. The several BRC motifs in the protein bind the RAD51 recombinase and thus enable DNA repair. The protein consists of 3418 amino acids with a weight of 384 kDa.

Gene name

STK11 (serine/threonine kinase 11)

Location

19p13.3

Note

Mutation of this tumor suppressor gene causes the autosomal dominant Peutz-Jeghers-Syndrome which is characterized by intestinal polyposis and pigmented naevi as well as increased tumor risk (Jeghers et al., 1949; Giardiello et al., 1987). The protein is regulated by androgens and estrogen in adipocytes (McInnes et al., 2012).

Dna rna description

The gene consists of 10 exons which encompass 23 kb.

Protein description

The protein regulates cell polarity and functions as a tumor suppressor. It consists of 433 amino acids with a weight of 48.6 kDa.

Gene name

ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian))

Location

17q12

Note

Other names: HER-2/neu, c-erbB-2.

Dna rna description

31 exons, 2 mRNA variants encoding 2 proteins: isoform a and b.

Protein description

This protein is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. It forms heterodimers with other EGFRs that (unlike ErbB-2) have a ligand binding domain and can thus initiate intracellular signaling leading to activation of pathways such as mTOR or PI3K. Overexpression is known for several cancers such as breast and ovarian but also fallopian tube carcinomas.
Based on a cohort of 43 patients with fallopian tube carcinoma, Lacy et al. reported immunohistochemical positivity for c-erbB-2 (HER-2/neu) overexpression in 26% and p53 positivity in 61% of all cases. They could not find any correlation with survival (Lacy et al., 1995).

Gene name

TP53 (Tumour protein p53 (Li-Fraumeni syndrome))

Location

17p13.1

Note

Tumor protein p53.

Dna rna description

11 exons, 8 transcript variants encoding 7 protein isoforms (http://www.ncbi.nlm.nih.gov/gene/7157#reference-sequences).

Protein description

p53 is a tumor suppressor protein that is synthesized in response to cellular stress. It causes cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism via DNA binding. The binding of p53 leads to transcriptional activation of several genes. Mutations are known from several human tumors and also for hereditary tumor syndroms like Li-Fraumeni-Syndrome. Transcription activation is triggered by a homo-tetrameric p53 complex in which mutant isoforms are dominant over the wild-type protein. Moreover, functional p53 induces its own degradation (with a half-life of 15-30 min) whereas mutant p53 accumulates and thus enables immunohistochemical detection.
Examining a cohort of 43 patients with fallopian tube carcinoma, Lacy et al. found immunohistochemical positivity for c-erbB-2 (HER-2/neu) overexpression in 26% and p53 positivity in 61% of these tumors, but no significant correlation with survival (Lacy et al., 1995). Others, however, described p53 immunohistochemical positivity to be associated with shorter survival (Zheng et al., 1997; Rosen et al., 2000) whereas FIGO stages were not predictive for the outcome in this cohort of 63 patients (Rosen et al., 2000). Using 52 cases of fallopian tube carcinoma and 10 normal fallopian tubes, Zheng et al. investigated the p53 status based on immunohistochemistry and polymerase chain reaction-single-strand conformation polymorphisms (PCR-SSCP) and suggested that p53 alterations play a role in early tumor progression as they are not restricted to late stages (Zheng et al., 1997). Chung and colleagues found that survival neither correlated with immunohistochemical p53 positivity nor with cMyc overexpression (which occured in 61%). However, the statistical power of this study was limited by the small cohort of 18 patients (Chung et al., 2000).

Gene name

MYC v-myc myelocytomatosis viral oncogene homolog (avian)

Location

8q24.21

Dna rna description

3 exons, 1 variant, 1 isoform.

Protein description

The protein plays a role in cell cycle and apoptosis. It functions as transcription factor. Overexpression is known in several cancers especially leukaemias and lymphomas like Burkitts lymphoma. Chung and colleagues found that survival neither correlated with immunohistochemical p53 positivity nor with cMyc overexpression (which occured in 61%). However, the statistical power of this study was limited by the small cohort of 18 patients (Chung et al., 2000).

To be Noted

Note

Acknowledgement: We would like to thank Prof. Dr. med. Eva Geißinger and Dr. med. Camelia-Maria Monoranu, Institute of Pathology at Würzburg University, for supporting this publication with histopathological material and helpful discussions.

Bibliography

Pubmed IDLast YearTitleAuthors
225292652012OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.Aghajanian C et al
157956322005Primary fallopian tube carcinoma.Ajithkumar TV et al
75907021995Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.Ambros RA et al
92887651997Fine mapping of a genetic locus for Peutz-Jeghers syndrome on chromosome 19p.Amos CI et al
89106381996alpha-Fetoprotein-producing (hepatoid) carcinoma of the fallopian tube.Aoyama T et al
33717421988Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases.Asmussen M et al
112639282001A genetic epidemiological study of carcinoma of the fallopian tube.Aziz S et al
110660482000Carcinoma of the fallopian tube.Baekelandt M et al
84143201993Second-look laparotomy in carcinoma of the fallopian tube.Barakat RR et al
24694071989Metaplastic papillary tumor of the fallopian tube. Case report, immunohistochemical features, and review of the literature.Bartnik J et al
97797111998Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Bookman MA et al
50963631971Clinical aspects of primary carcinoma of the Fallopian tube: a clinical study of 14 cases.Boutselis JG et al
330911978Ectopic pregnancy coexisting with a primary carcinoma of the Fallopian tube: a case report.Carapeto R et al
187573302008Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.Carlson JW et al
79435331994Pseudocarcinomatous hyperplasia of the fallopian tube associated with salpingitis. A report of 14 cases.Cheung AN et al
106293732000Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma.Chung TK et al
126496642003Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations.Colgan TJ et al
15827461992Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a report of six cases.Daya D et al
39604151986Primary choriocarcinoma of the fallopian tube. Report of a case with survival and postoperative delivery. Review of the literature.Dekel A et al
112931572001Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study.Demopoulos RI et al
71915481980Combination chemotherapy for advanced carcinoma of the fallopian tube.Deppe G et al
218493002011The post-reproductive Fallopian tube: better removed?Dietl J et al
223805322012Primary adenomyoma of the fallopian tube mimicking tubal malignant tumor.Etoh T et al
192371872009Precursors to pelvic serous carcinoma and their clinical implications.Folkins AK et al
85337571995Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.Friedman LS et al
113309422001Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.Gadducci A et al
111365632001Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.Gemignani ML et al
35872801987Increased risk of cancer in the Peutz-Jeghers syndrome.Giardiello FM et al
37216981986Obstructing fallopian tube papilloma.Gisser SD et al
85222671995Two unusual presentations of müllerian adenosarcoma: case reports, literature review, and treatment considerations.Gollard R et al
109636372000Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.Gordon AN et al
127780002003Immunohistochemical profile of serous papillary cystadenofibroma of the fallopian tube: a clue of paramesonephritic origin.Gürbüz Y et al
62472521980Malignant mixed Mullerian tumor of the fallopian tube. Report of a case and review of literature.Hanjani P et al
107490232000Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery.Hartley A et al
118274292001Polyp of the fallopian tube.Heatley MK et al
20080081991Adenomatous polyp of the fallopian tube. A case report.Heller DS et al
115784431994DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer.Hellström AC et al
1958691977Primary carcinoma of the fallopian tube: difficulties of diagnosis and treatment.Henderson SR et al
27375211989Clinical study of primary carcinoma of the fallopian tube: experience with 15 cases.Hirai Y et al
96262251998Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.Hoskins P et al
107397142000Metachronous carcinoma of the vulva and fallopian tube.Ichikawa Y et al
153041522004Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital.Inal MM et al
113285382001Tubal ectopic pregnancy associated with an adenomatoid tumor.Inoue T et al
81126531993Primary leiomyosarcoma of the fallopian tube.Jacoby AF et al
153982451949Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance.JEGHERS H et al
123549342002Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.Jongsma AP et al
33506191988Metaplastic papillary tumor of the fallopian tube: a case report with ultrastructure.Keeney GL et al
223319122012High-grade serous ovarian cancer arises from fallopian tube in a mouse model.Kim J et al
172557602007Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.Kindelberger DW et al
27220621989Fallopian tube carcinoma: a clinicopathological study of 17 cases.King A et al
118256692002Tumor progression, histologic grading and DNA-ploidy as predictive factors of lymphogenous metastasis in primary carcinoma of the Fallopian tube.Klein M et al
106600901999Lymphadenectomy in primary carcinoma of the Fallopian tube.Klein M et al
121448272002Treatment and survival for women with Fallopian tube carcinoma: a population-based study.Kosary C et al
204314792010Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.Kuhn E et al
1823511976Trophoblastic pseudotumor of the uterus: an exaggerated form of "syncytial endometritis" simulating a malignant tumor.Kurman RJ et al
77739391995c-erbB-2 and p53 expression in fallopian tube carcinoma.Lacy MQ et al
231891652012Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Lanitis E et al
171173912007A candidate precursor to serous carcinoma that originates in the distal fallopian tube.Lee Y et al
113284182001Paraneoplastic cerebellar degeneration heralding fallopian tube adenocarcinoma.Levite R et al
102026791999Mixed malignant germ cell tumor of the fallopian tube.Li S et al
35571961987Primary carcinoma of the fallopian tube: evidence for activity of cisplatin combination therapy.Maxson WZ et al
31696901988A fallopian tube lesion of borderline malignancy associated with pseudo-myxoma peritonei.McCarthy JH et al
218765482012Regulation of LKB1 expression by sex hormones in adipocytes.McInnes KJ et al
37568221986Carcinoma of the fallopian tube. Management and sites of failure.McMurray EH et al
57424791968Primary adenocarcinoma of the fallopian tube.Momtazee S et al
90605371997Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Muggia FM et al
20134521991Combination chemotherapy in advanced adenocarcinoma of the fallopian tube.Muntz HG et al
89468741996Endometrioid carcinoma of the fallopian tube: a clinicopathologic analysis of 26 cases.Navani SS et al
70351131981Gestational choriocarcinoma of the fallopian tube.Ober WB et al
66272081983Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases.Osborne BM et al
169513942006Fallopian tube carcinoma: a review.Pectasides D et al
33576641988Prognostic features of carcinoma of the fallopian tube.Peters WA 3rd et al
185466202008Ovarian carcinogenesis: an alternative hypothesis.Piek JM et al
108697912000Primary carcinoma of the fallopian tube: study of 11 cases.Piura B et al
208617112010Are all pelvic (nonuterine) serous carcinomas of tubal origin?Przybycin CG et al
84629031993Immunohistochemical staining for CA-125 in fallopian tube carcinomas.Puls LE et al
72956031981Primary carcinoma of the fallopian tube. Report of 22 cases.Raju KS et al
125948212003Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97.Riska A et al
22492081990Fallopian tube cancer. The Roswell Park experience.Rose PG et al
83530511993Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.Rosen A et al
108401532000p53 expression in fallopian tube carcinomas.Rosen AC et al
100260261999Management and prognosis of primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.Rosen AC et al
28070171989Incidence of malignant fallopian tube tumors.Rosenblatt KA et al
74059041980Metaplastic papillary tumor of the fallopian tube--a distinctive lesion of pregnancy.Saffos RO et al
55663591971Staging and prognosis in primary carcinoma of the fallopian tube.Schiller HM et al
112146132000Primary carcinoma of the fallopian tube. A report of 19 cases with literature review.Schneider C et al
6444221978Carcinoma of the fallopian tube.Sedlis A et al
211593682011"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.Seidman JD et al
79779431994Mucinous lesions of the fallopian tube. A report of seven cases.Seidman JD et al
219795882011Anti-Yo antibody associated with occult fallopian tube carcinoma.Selby KJ et al
35172661986Adenomatoid tumours: an immunohistochemical and ultrastructural appraisal of their histogenesis.Stephenson TJ et al
179616422007The incidence of primary fallopian tube cancer in the United States.Stewart SL et al
103290551999Pregnancy with primary tubal placental site trophoblastic tumor--A case report and literature review.Su YN et al
109856122000Treatment of fallopian tube cancer. Review of the literature.Takeshima N et al
72827871981Adenocarcinoma of the uterine tube: potential for lymph node metastases.Tamimi HK et al
161262582005Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma.Tanaka Y et al
77590761995Linkage analysis of 26 Canadian breast and breast-ovarian cancer families.Tonin P et al
88987351996Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.Tonin P et al
76221161995Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel.Tresukosol D et al
125293432003International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.Trimbos JB et al
84024621993Transitional cell carcinoma pattern in primary carcinoma of the fallopian tube.Uehira K et al
232406692013Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.Vang R et al
115762821998Survival of patients with primary fallopian tube carcinoma.Vaughan MM et al
71857641982Primary clear cell adenocarcinoma of the fallopian tube: light microscopic and ultrastructural findings.Voet RL et al
228365112012Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.Wagner U et al
57659641969Multiple malignancy in the upper genital canal.Woodruff JD et al
115784381994What is the true incidence of primary fallopian tube carcinoma?Woolas R et al
198349512010The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.Xian W et al
4713641979Carcinoma of the fallopian tube.Yoonessi M et al
93899391997An unusual case of a renin-producing tumour of the fallopian tube.Zabernigg A et al
89955451997Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube.Zheng W et al
85406061996Borderline papillary serous tumour of the fallopian tube.Zheng W et al
106204402000Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.Zweemer RP et al

External Links

Citation

Roland Gregor Stein ; Joachim Diessner ; Arnd Hönig ; Jörg Wischhusen ; Johannes Dietl

Fallopian tube tumors: an overview

Atlas Genet Cytogenet Oncol Haematol. 2013-03-01

Online version: http://atlasgeneticsoncology.org/solid-tumor/5279/fallopian-tube-tumors-an-overview